InvestorsHub Logo
Followers 4
Posts 1191
Boards Moderated 0
Alias Born 10/03/2015

Re: None

Monday, 06/06/2016 3:02:40 PM

Monday, June 06, 2016 3:02:40 PM

Post# of 977
NKTR-214 is a CD122-biased agonist designed to stimulate the patient's own immune system to kill tumor cells by preferentially activating production of specific immune cells which promote tumor killing, including CD8-positive T cells and Natural Killer (NK) cells, within the tumor micro-environment. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase proliferation of these types of T cells.

http://finance.yahoo.com/news/preclinical-data-presented-asco-2016-180000640.html